shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer

HER2(+) breast cancer is currently treated with chemotherapy plus anti-HER2 inhibitors. Many patients do not respond or relapse with aggressive metastatic disease. Therefore, there is an urgent need for new therapeutics that can target HER2(+) breast cancer and potentiate the effect of anti-HER2 inh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2014-04, Vol.74 (7), p.2119-2130
Hauptverfasser:	TAO DENG, LIU, Jeff C, EGAN, Sean E, AL-AWAR, Rima, MOFFAT, Jason, ZACKSENHAUS, Eldad, CHUNG, Philip E. D, UEHLING, David, AMAN, Ahmed, JOSEPH, Babu, KETELA, Troy, ZHE JIANG, SCHACHTER, Nathan F, ROTTAPEL, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Apoptosis - drug effects Autophagy Autophagy-Related Protein-1 Homolog Biological and medical sciences Breast Neoplasms - chemistry Breast Neoplasms - genetics Breast Neoplasms - pathology Breast Neoplasms - therapy Cell Cycle Checkpoints - drug effects Cell Line, Tumor Female Genes, p53 Gynecology. Andrology. Obstetrics Humans Intracellular Signaling Peptides and Proteins - antagonists & inhibitors Mammary gland diseases Medical sciences Mice Mice, SCID Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Pharmacology. Drug treatments Protein-Serine-Threonine Kinases - antagonists & inhibitors Quinazolines - pharmacology Receptor, ErbB-2 - analysis RNA, Small Interfering - genetics Transcription Factor RelA - antagonists & inhibitors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!